Monitor for Phase 2 trial initiations in ARDS and GVHD in 1H 2026, with early data expected by year-end. The non-dilutive funding and cash runway through 2026 reduce near-term financing risk, making clinical readouts the key value drivers.
INKT drugs
INKT drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 31 $10.53entry
- T+1 · 8mo ago +0.38%α −0.37% · $10.57
- T+5 · 7mo ago +5.89%α +1.94% · $11.15
- T+20 · 7mo ago +4.61%α −4.82% · $11.02
- T+60 · 5mo ago +10.54%α −1.84% · $11.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics reported Q4 2025 financial results showing a narrower-than-expected net loss of $0.56 per share (beat vs $0.68 consensus), driven by non-dilutive funding and advancing clinical programs. Key catalysts include Phase 2 trials for ARDS/hypoxemic pneumonia (initiation in 1H 2026, data by year-end) and graft-versus-host disease (first dosing expected May 2026), supported by NIH and philanthropic grants. The company ended 2025 with $13.4M cash, extended to 2026 via $3M raised from its ATM program.
Key Financial Metrics
Key Facts
- Q4 2025 net loss of $2.6M ($0.56/share), beating consensus of $0.68/share.
- Phase 2 trial for ARDS/hypoxemic pneumonia to initiate in 1H 2026, with early data expected by year-end.
- GVHD program fully funded by NIH STTR grant and Mary Gooze award; first patient dosing expected May 2026.
- Ended 2025 with $13.4M cash; raised $3M since year-end via ATM, providing runway through 2026.
- Appointed Melissa Orilall as Principal Financial Officer and Col. (Ret.) John Holcomb to the Board.
Financial Impact
Net loss of $2.6M ($0.56/share) for Q4 2025, beating consensus by $0.12/share.
Risk Factors
- High cash burn typical of early-stage biotech; future dilution possible if additional funding is needed.
- Clinical trial delays or negative data could significantly impact stock price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-133346 |
| Document: inkt-ex99_1.htm | 0001193125-26-133346 |
| Document: 0001193125-26-133346-index-headers.html | 0001193125-26-133346 |
| Document: 0001193125-26-133346-index.html | 0001193125-26-133346 |
| Document: 0001193125-26-133346.txt | 0001193125-26-133346 |
| 8-K Data (Synthetic) | 0001193125-26-133346 |
Track record
21 reports on INKT
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers